Why the study?
Does atorvastatin reduce hs-CRP levels in patients with new-onset type 2 diabetes, normal blood lipids, and macrovascular disease?
Does atorvastatin reduce hs-CRP levels in patients with new-onset type 2 diabetes, normal blood lipids, and macrovascular disease?
Atorvastatin 10 mg daily for 12 weeks significantly reduces hs-CRP levels in patients with new-onset type 2 diabetes, normal lipids, and macrovascular disease.
Answers are grounded in this paper and cite their sources.
Supports atorvastatin for inflammation reduction in new-onset T2DM with macrovascular disease despite normal lipids; extends pleiotropic evidence to this population.
Objective To observe influence of atorvastatin to high sensitive C-reactlve protein in the new on-set type 2 diabetes of normal blood lipid with macrovascular disease. Methods 96 cases with the new onset type 2 diabetes of normal blood lipid with macrovascu]ar disease were randomly divided into two groups,the treatment group contains 49 cases who were given atorvastatin 10rag for 12 weeks,the control group contains 47 cases who were given placebo for 12 weeks. Two groups were underwent the following test,fasting plasma glucose(FBG) ,post-OGTT 2 hour plasma glucose(PPG) ,glycosy-lated hemoglobin(HbAic) ,total triglyceride(TG) ,total cholesterol(TC) ,low density lipoprotein cholesterol(LDL-C) ,high sensitive C-reactive protein(hs-CRP). Results High sensitive C-reactive pro-tein(hs-CRP) in treatment group is significantly lower than control group[(2.13±1.38) mg/L and (4.04±3.14) mg/L,P < 0.05]. Conclusion Atorvastatin can significantly decease the level of high sensitive C-reactive protein (hs-CRP) to the new onset type 2 diabetes of normal blood lipid with macrovascular disease.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: